2017
DOI: 10.1007/978-1-4939-7459-7_21
View full text
|
|
Share

Abstract: The TARDIS assay was originally developed as a means of detecting and quantifying melphalan and cisplatin DNA adducts at the single cell level, but it has since been adapted to quantify topoisomerase DNA complexes that result from the actions of topoisomerase poisons and this is currently the main use of the assay. The method employs sensitive immunofluorescent detection to quantify topoisomerase molecules covalently coupled to DNA in what are often referred to as cleavage complexes. Free topoisomerase molecul…

expand abstract